Background: Our previous publication showed that 9% of patients with a history of myocardial infarction MI. could be labeled as aspirin resistant; all of these patients were aspirin resistant because of non-compliance. This report compares the relative frequency of aspirin resistance between known compliant and non-compliance subjects to demonstrate that non-compliance is the predominant cause of aspirin resistance.

Methods: The difference in the slopes of the platelet prostaglandin agonist (PPA) light aggregation curves off aspirin and 2 hours after observed aspirin ingestion was defined as net aspirin inhibition.

Results: After supposedly refraining from aspirin for 7 days, 46 subjects were judged non-compliant with the protocol. Of the remaining 184 compliant subjects 39 were normals and 145 had a past history of MI. In known compliant subjects there was no difference in net aspirin inhibition between normal and MI subjects. Net aspirin inhibition in known compliant patients was statistically normally distributed. Only 3% of compliant subjects (2 normals and 5 MI) had a net aspirin inhibitory response of less than one standard deviation which could qualify as a conservative designation of aspirin resistance. A maximum of 35% of the 191 post MI subjects could be classified as aspirin resistant and/or non-compliant: 9% aspirin resistant because of non-compliance, 23% non-compliant with the protocol and possibly 3% because of a decreased net aspirin inhibitory response in known compliant patients.

Conclusion: Our data supports the thesis that the predominant cause of aspirin resistance is noncompliance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538501PMC
http://dx.doi.org/10.1186/1479-5876-6-46DOI Listing

Publication Analysis

Top Keywords

net aspirin
20
aspirin
17
aspirin resistance
16
aspirin resistant
16
predominant aspirin
12
compliant subjects
12
non-compliance predominant
8
resistant non-compliance
8
non-compliant protocol
8
subjects normals
8

Similar Publications

Photothermal-manipulatable shape memory polyacrylamide/gelatin Janus hydrogel with drug carrier array for invasive wound closure and responsive drug release.

Int J Biol Macromol

December 2024

State Key Laboratory of Resource Insects, College of Sericulture, Textile and Biomass Sciences, Southwest University, Chongqing 400715, China. Electronic address:

Traditional wound closure methods often present several issues, including additional puncture wounds, adverse effects from anesthesia, and noticeable scarring. Inspired by embryonic wound healing, a Janus hydrogel (PG/Au-Asp@PCM) is designed to manipulate non-invasive wound closure by photothermal-responsive self-contraction of PG/Au-Asp@PCM, which is attributed to the shape memory behavior of PG/Au-Asp@PCM under near-infrared (NIR). Wherein, gelatin acts as a thermally reversible "switch" and polyacrylamide creates stable and cross-linked "net-points".

View Article and Find Full Text PDF

Indobufen-based Dual Antiplatelet Therapy in Patients with Multivessel Coronary Disease Undergoing Drug-eluting Stent Implantation Insight From the OPTION Trial.

Am Heart J

December 2024

Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China; Department of Cardiology, Shanghai Geriatric Medical Center, Shanghai, China. Electronic address:

Background: It remains unclear whether indobufen-based dual antiplatelet therapy (DAPT) preserves ischemic protection while limiting bleeding risk in patients with multivessel coronary disease (MVD). This study aimed to investigate the efficacy and safety of indobufen-based DAPT in patients with MVD.

Methods: Patients in the OPTION trial were stratified based on the presence of MVD.

View Article and Find Full Text PDF

Optimal Long-term Antiplatelet Regimen for Patients with High Ischaemic and Bleeding Risks After Percutaneous Coronary Intervention.

Thromb Haemost

December 2024

Internal Medicine, Cardiovascular Centre, Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang National University Changwon Hospital, Changwon-si, Korea (the Republic of).

Aim To assess an optimal long-term antiplatelet strategy in patients at both high ischaemic and bleeding risks after percutaneous coronary intervention (PCI). Methods and results Patients both at high ischaemic and bleeding risks were eligible for inclusion. We excluded patients with any ischaemic and major bleeding complications during the mandatory period of dual antiplatelet therapy (DAPT).

View Article and Find Full Text PDF

A 55-year-old male with hemophilia A came to the outpatient clinic with chest pain for several days after overdose injection of coagulation factor. He was a heavy smoker and a chronic alcoholic. An electrocardiogram (ECG) showed no specific change.

View Article and Find Full Text PDF
Article Synopsis
  • Anti-Phospholipid Antibodies (aPL) increase the risk of blood clots, and the effectiveness of antiplatelet drugs for preventing these clots in aPL carriers was evaluated through a systematic review of existing studies.
  • The review included 1056 participants and found that low-dose acetylsalicylic acid (LDA) significantly reduced both arterial and venous thrombotic events compared to control groups without increasing major bleeding risks.
  • However, the safety and benefit of LDA may vary depending on the specific aPL profile of the individuals, which remains uncertain.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!